Navigation Links
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
Date:6/28/2009

e three pivotal phase III studies demonstrated that add-on therapy with once-daily Zebinix(R) (800mg and 1200mg) was effective in reducing partial-onset seizures in patients not controlled with one of the most commonly used anti-epileptics, carbamazepine (CBZ), (p<0.01 and p<0.0001 respectively)(3).

Across the clinical studies conducted, eslicarbazepine acetate has demonstrated a favourable safety profile(5). This has been further reinforced by a pooled analysis indicating that most adverse events begin within the first weeks of treatment but after six weeks, no relevant difference was found between eslicarbazepine acetate and placebo(4).

Zebinix(R), researched and developed by BIAL, received marketing authorisation from the European Commission in April 2009, as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation. Under the terms of a deal with BIAL, announced in February this year, Eisai Europe Ltd received a sole license to market, promote and distribute ESL within Europe**. Eisai and BIAL plan to launch Zebinix(R) across Europe during 2009 and into 2010, providing a novel and effective treatment to patients with partial-onset seizures who are not adequately controlled with their existing medications. The rights to commercialise the product in the U.S. and Canadian markets were licensed to Sepracor Inc., in late 2007 (the proposed name for eslicarbazepine acetate in the U.S. and Canada is STEDESA(TM)). In June 2009, Sepracor announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) for STEDESA(TM) as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy, and the NDA is currently under formal review.

Notes to Editors

* Zebinix(R) is the EU trade name for eslicarbazepine acetate.

** European Territories

Austria, Belgium, Bulga
'/>"/>

SOURCE BIAL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
2. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
3. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
4. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
11. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Rogne Bioscience, a privately-held biotechnology company ... preclinical and mechanism of action data will be presented ... Dermatology (SID) Annual Meeting being held May 6-9, 2015 ... . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... a novel, low MW (<1700 daltons) peptide as a ...
(Date:5/4/2015)... , May 4, 2015 Bayer HealthCare (Bayer) ... Pharmaceuticals, Inc. (NASDAQ: ISIS ) on ISIS-FXI Rx, ... the prevention of thrombosis. Under the agreement Bayer will ... of high unmet medical need. As part of the ... profile of ISIS-FXI Rx in an appropriate patient ...
(Date:5/4/2015)...  Clinical Support Services, Inc. (CSS) Resident Pharmacist, ... analysis of Pharmacologic Adverse Events in patients with ... Services, Inc. clinical staff were used to conduct ... psychiatric medications to assess the frequency of adverse ... patients experienced at least one ADE and 87% ...
Breaking Medicine Technology:Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3
... Oct. 19 Mylan Inc. (Nasdaq: MYL ) ... stock issuance, the company has declared its quarterly dividend of ... 6.5% and a liquidation preference of $1,000.00 per share) payable ... record as of Nov. 1, 2010.  Nov. 15, is also ...
... Oct. 19 Reportlinker.com announces that a new ... Renal Cell Carcimona Cancer Drug ... AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING ... Espicom,s Renal Cell Carcinoma Cancer Drug Futures includes ...
Cached Medicine Technology:Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 2Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 3Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 4Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 5Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 6Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 7Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 8Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures 9
(Date:5/4/2015)... 2015 METTLER TOLEDO has announced ... Data Integrity in a GXP Regulated Laboratory ", ... This webinar will be presented on May 27, ... integrity is a critical component of pharmaceutical product ... However, in recent years an increasing number of ...
(Date:5/4/2015)... NORTH HOLLYWOOD, Calif. (PRWEB) May 04, 2015 ... awards program recognizes IPC clinical leaders who have made ... to the patients they serve, both in acute and ... Hospitalist of the Year, Post-Acute Provider of the Year, ... the Year and Specialist Provider of the Year. Recipients ...
(Date:5/4/2015)... EY today announced that Kevin MacDonald, CEO and ... EY Entrepreneur Of The Year® 2015 Award in the ... who demonstrate excellence and extraordinary success in such areas ... businesses and communities. Mr. MacDonald was selected as ... Award winners will be announced on Thursday, June 18, ...
(Date:5/4/2015)... Los Angeles dental implants ... comfortable and attractive alternative for patients with dentures. Dentures ... who have lost teeth. Unfortunately, they also require some ... at the worst possible moment and may make clicking ... also painfully pinch or rub gums, leaving sores and ...
(Date:5/4/2015)... May 04, 2015 Ticket Down is a ... Colonial Life Arena in Columbia, South Carolina. Fans ... of his “Out There” tour which originally kicked off in ... is North America and the legendary performer recently announced that ... Wells Fargo Arena on June 21st, in Charlottesville, VA at ...
Breaking Medicine News(10 mins):Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Sept. 8 ... first-grade class when the hijacked planes with their terrified passengers ... that day are incomplete, they,re burned into her memory just ... seeing her mother glued to the TV, watching the Twin ...
... In light of a national survey showing that only about ... a compassionate one, the Schwartz Center for Compassionate Healthcare today ... in the September issue of Health Affairs , the ... compassionate care matters because it is fundamental to the practice ...
... broad panel of leaders representing health care, academic medicine, ... the content and format of U.S. graduate medical education ... and efficiently to meet public needs. The ... overhauling the training of newly minted physicians - "residents" ...
... for a second stroke who received intensive medical treatment had ... stent in addition to the medical treatment, a large nationwide ... online first edition of the New England Journal of ... of the clinical research sites for the study. ...
... , THURSDAY, Sept. 8 (HealthDay News) -- The bigger ... RAND Corp. study finds. The researchers found a roughly ... fewest health plans. The reason for this decline, they said, ... lower prices from health providers. This consolidation, the study concluded, ...
... 8, 2011The number of underinsured adultsthose with health insurance all ... their incomesrose by 80 percent between 2003-2010, from 16 million ... published in the September issue of Health Affairs. Nearly half ... in 2010, up from 75 million in 2007 and 61 ...
Cached Medicine News:Health News:9/11 a Life-Defining Day for the Young 2Health News:9/11 a Life-Defining Day for the Young 3Health News:9/11 a Life-Defining Day for the Young 4Health News:Schwartz Center proposes agenda to promote compassionate care 2Health News:Schwartz Center proposes agenda to promote compassionate care 3Health News:Macy Foundation report calls for sweeping graduate medical education reforms 2Health News:Macy Foundation report calls for sweeping graduate medical education reforms 3Health News:Macy Foundation report calls for sweeping graduate medical education reforms 4Health News:Stroke prevention trial finds intensive medical treatment has better results than brain stenting 2Health News:Stroke prevention trial finds intensive medical treatment has better results than brain stenting 3Health News:Big Health Plans Can Negotiate Lower Hospital Costs: Study 2Health News:Insured and still at risk: Number of underinsured increased 80 percent between 2003 - 2010 2Health News:Insured and still at risk: Number of underinsured increased 80 percent between 2003 - 2010 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: